Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26235261 | 0.93 | POLRMT (0.46) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26238995 | 0.91 | POLRMT (0.48) | POLRMTDOT1LCSNK2A2CSNK2A1STING1 | |
| SCHEMBL26832849 | 0.91 | POLRMT (0.46) | POLRMTDOT1LCSNK2A2CSNK2A1STING1 | |
| SCHEMBL26828450 | 0.91 | POLRMT (0.47) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26832737 | 0.90 | POLRMT (0.45) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26831777 | 0.90 | POLRMT (0.47) | POLRMTDOT1LCSNK2A2CSNK2A1STING1 | |
| SCHEMBL26235258 | 0.90 | POLRMT (0.46) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26230098 | 0.90 | POLRMT (0.48) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26235465 | 0.89 | POLRMT (0.44) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26230341 | 0.89 | POLRMT (0.49) | POLRMTDOT1LSTING1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023168254-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | POLRMT 13/4885DOT1L 2954/4885CSNK2A2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.